Pfizer’s drug meets main goal in late-stage blood cancer trial

(Reuters) – Pfizer said on Tuesday a combination treatment using its drug, Adcetris, met its main goal of overall survival when tested in patients with a type of blood cancer.

(Reporting by Pratik Jain; Editing by Shailesh Kuber)